Conclusion:The study will provide important data on the effectiveness of daratumumab either alone or in combination with ASCT in the treatment of both kidney and hematological conditions on various MGRS diseases.I have potential conflict of interest to disclose.Grant from Janssen-Cilag to conduct the study.I did not use generative AI and AI-assisted technologies in the writing process.
Yahata et al. (Wed,) studied this question.